Background: Precise functional capacity assessment is a critical component for preoperative risk stratification. Brief submaximal cardiopulmonary exercise testing (smCPET) has shown diagnostic utility in various cardiopulmonary conditions. Objective: The objective of this study was to determine if smCPET could be implemented in a high-volume pre-surgical evaluation clinic, and, when compared to structured functional capacity surveys, if smCPET could better discriminate low functional capacity (<4.6 METs). Measured endpoints were: operational efficiency by time of experimental session < 20 minutes, modified Borg survey of perceived exertion of <7 indicating no more than moderate exertion, high participant satisfaction with smCPET task execution, represented as a score of >8 (of 10), and high participant satisfaction with smCPET scheduling, represented as a score of >8 (of 10). Methods: After institutional approval, 43 participants presenting for noncardiac surgery who met the following inclusion criteria: age > 60 years old, revised cardiac risk index of <2, and self-reported metabolic equivalents (METs) of >4.6 (self-endorsed ability to climb 2 flights of stairs), were enrolled. Subjective METs, Duke Activity Status Index (DASI) surveys, and a 6-minute smCPET trial were performed. Student's t test was used to determine significance of the secondary endpoint. Correlation between comparable structured survey and smCPET measurements were assessed using Pearson's correlation coefficient. A Bland-Altman analysis was used to assess agreement between methods. Results: Session time was 16.9 minutes (±6.8). Post-test modified Borg survey was 5.35 (±1.8). Median (IQR) patient satisfaction [on a scale of 1 (worst) to 10 (best)] was 10 (10,10) for scheduling and 10 (9, 10) for task performance. Subjective METs were higher, when compared to smCPET equivalent (extrapolated peak METs) [7.6 (±2.0) vs. 6.7 (±1.8), df 42, P<.001]. DASI-estimated peak METs was higher when compared to smCPET peak METs [8.8 (±1.2) vs. 6.7 (±1.8), df 42, P<.001]. DASI-estimated peak VO2 was higher than smCPET peak VO2 [30.9 ml.kg-1.min-1 (±4.3) vs. 23.6 ml.kg-1.min-1 (±6.5), df 42, P<.001]. Conclusions: Implementation of smCPET in a pre-surgical evaluation clinic is both patient-centered and clinically feasible. Brief smCPET measures, supportive of published reports regarding low sensitivity of provider-driven or structured survey measures for low functional capacity, were lower than structured surveys. Future studies will analyze prediction of perioperative complications and cost effectiveness. Trial Registration: ClinicalTrials.gov NCT05743673. https://clinicaltrials.gov/study/NCT05743673.

Download full-text PDF

Source
http://dx.doi.org/10.2196/65805DOI Listing

Publication Analysis

Top Keywords

functional capacity
12
submaximal cardiopulmonary
8
high-volume pre-surgical
8
pre-surgical evaluation
8
evaluation clinic
8
subjective mets
8
smcpet
6
implementation submaximal
4
cardiopulmonary testing
4
testing high-volume
4

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

AIMST University, Bedong, Kedah, Malaysia.

Background: Senile dementia (SD) is a deteriorative organic brain disorder and it comprises Alzheimer's disease (AD) as a major variant. SD is shown impairment of mental capacities whereas AD is degeneration of neurons. According to World Health Organization (WHO) report; more than 55 million peoples have dementia and it is raising 10 million new cases every year.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Retromer Therapeutics, New York, NY, USA.

Background: Convergent evidence indicates that deficits in the endosomal recycling pathway underlies pathogenesis of Alzheimer's disease (AD). SORL1 encodes the retromer-associated receptor SORLA that plays an essential role in recycling of AD-associated cargos such as the amyloid precursor protein and the glutamatergic AMPA receptor. Importantly, loss of function pathogenic SORL1 variants are associated with AD.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Genentech, Inc., South San Francisco, CA, USA.

Background: Clinical outcome assessments (COAs) that measure functional capacities are key tools to evaluate efficacy in Alzheimer's disease (AD) clinical trials. The Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) scale is frequently used to assess changes in both basic and instrumental activities of daily living, but there is no clear consensus on what magnitude of change on this scale may be considered clinically meaningful. To address this question, we conducted anchor-based analyses (as recommended by the FDA) to explore meaningful within-patient/participant change thresholds on the ADCS-ADL.

View Article and Find Full Text PDF

Background: Homozygosity for the rare APOE3-Christchurch (APOE3Ch) variant, encoding for apoE3-R136S (apoE3-Ch), was linked to resistance against an aggressive form of familial Alzheimer's disease (AD). Carrying two copies of APOE3Ch was sufficient to delay autosomal AD onset by 30 years. This remarkable protective effect makes it a strong candidate for uncovering new therapies against AD.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Division of Neurodegenerative Disorders, St. Boniface Hospital Albrechtsen Research Centre, Winnipeg, MB, Canada.

Background: Alzheimer's disease (AD) is a neurodegenerative disorder primarily associated with aging, but manifests as a complex interplay of multiple factors. Decline in sex-hormones, particularly 17-beta estradiol, is linked to the aging process. The risk for onset of AD significantly increases with aging and loss of estradiol.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!